# Modelling complete dynamics of SARS-CoV-2 pandemics of Germany and its federal states using multiple levels of data

Yuri Kheifetz \*, Holger Kirsten, Andreas Schuppert and Markus Scholz \*

Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Haertelstrasse 16-18, 04107 Leipzig, Germany; holger.kirsten@imise.uni-leipzig.de

- \* Correspondence: yuri.kheifetz@imise.uni-leipzig.de (Y.K.); markus.scholz@imise.unileipzig.de (M.S.);
	- Tel.: +49-341-97-16348 (Y.K.); +49-341-97-16190 (M.S.)

#### Abstract:

Epidemiological modelling is a key method of pandemic management including that of SARS-CoV-2. New insights into epidemiologic mechanics and new data resources require continuous adaptions of modelling approaches. We here present a revised and considerably extended version of our previous SARS-CoV-2 model implemented as input-output non-linear dynamical systems (IO-NLDS). We now include integration of age-dependent contact patterns, immune waning, and new data resources such as seropositivity studies, hospital dynamics, variant dynamics, non-pharmaceutical intervention measures and dynamics of the vaccination campaigns.

With this modelling framework, we explain the dynamics of several data resources for the complete pandemics in Germany as well as its 16 federal states. The latter also allows us to investigate the heterogeneity of model parameters in Germany for the first time. To achieve this goal, we extend our estimation approach by constraining variation of parameters among the federal states. This allows reliable estimation of a few thousand parameters using hundreds of thousands of data points.

Our approach can be generalized to other epidemic situations or even other areas of application, thus, supporting general pandemic preparedness.

Keywords: COVID-19; SARS-CoV-2 epidemiologic models; dark figure; parameter heterogeneity; parametrization; extended multi-compartment SIRtype model; Input-Output Non-Linear Dynamical System; Bayesian knowledge synthesis, Machine-Learning, pandemic preparedness

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

#### Introduction

and there are estimates that it will remain high for an unforeseen period of time.<br>Understanding SARS-CoV-2 induced dynamics at several levels of data is of high importance<br>for a proper risk management including planning o and there are estimated that it will remain high for an understanding SARS-CoV-2 induced dynamics at several levels of data is of high importance<br>for a proper risk management including planning of vaccination campaigns, no For a proper risk management including planning of vaccination campaigns, non-<br>pharmaceutical counter-measures, clinical resources and general pandemic preparedness. A<br>plethora of biomathematical models were proposed for t proposed a universal approach to parametrize mechanistic epidemiologic models using plethora of biomathematical models were proposed for that purpose but most of them only<br>describe the pandemics for a limited set of data or a limited time frame [1]. We recently<br>proposed a universal approach to parametrize plethoral describe the pandemics for a limited set of data or a limited time frame [1]. We recently<br>proposed a universal approach to parametrize mechanistic epidemiologic models using<br>multiple, often biased epidemiological proposed a universal approach to parametrize mechanistic epidemiologic models using<br>multiple, often biased epidemiological or clinical data sets. This approach is based on<br>embedding an epidemiologic model as a hidden layer proposed a universal approach to parametrize increasing provincingly invariantly<br>multiple, often biased epidemiological or clinical data sets. This approach is based on<br>embedding an epidemiologic model as a hidden layer in embedding an epidemiologic model as a hidden layer into an input-output non-linear dynamical system (IO-NLDS, [2]), where the input layer represents factors not known by the model such as changing non-pharmaceutical interv dynamical system (IO-NLDS, [2]), where the input layer represents factors not known by the model such as changing non-pharmaceutical interventions (NPI), vaccination campaigns or occurrence of new variants. The output layer represents different types of observational data which are linked to the hidden layer via occurrence of new variants. The output layer represents different types of observational data<br>which are linked to the hidden layer via so called data models addressing uncertainty and<br>bias of the observational data in rela which are linked to the hidden layer via so called data models addressing uncertainty and<br>bias of the observational data in relation to modelled state parameters. Unknown model<br>parameters can be estimated by a Bayesian app parameters can be estimated by a Bayesian approach using prior information of parameter<br>ranges derived from different external studies and other available data resources. parameters can be estimated by a Bayesian approach using prior information of parameter<br>ranges derived from different external studies and other available data resources.<br>With the help of this approach, with our previous m

parameters can be estimated by a Bayesian approach and other available data resources.<br>With the help of this approach, with our previous model we were able to describe pandemic<br>dynamics of Germany until April 2021 using an with the help of this approach, with our previous model we were able to describe<br>dynamics of Germany until April 2021 using an age-structured SIR-type model<br>layer. Several changes in the pandemic situation required an upda dynamics of Germany until April 2021 using an age-structured SIR-type model as hidden<br>layer. Several changes in the pandemic situation required an update of the underlying<br>epidemiologic model. These changes comprise for ex epidemiologic model. These changes comprise for example, (1) different contact behavior of age-groups, (2) modelling of final disease states of age-groups, (3) new replacement dynamics of variants including the possibility epidemiologic model. These changes comprise for example, (1) different contact behavior of age groups, (2) modelling of final disease states of age groups, (3) new replacement dynamics of variants including the possibility epidemic gas around states changes comprise the main perspect of states of a seg groups, (3) new replacement dynamics of variants including the possibility of more than two highly prevalent variants at the same time, and, dynamics of variants including the possibility of more than two highly prevalent variants at<br>the same time, and, (4) modelling of age-dependent vaccination efficacy, and, most<br>importantly, immune waning. the same time, and, (4) modelling of age-dependent vaccination efficacy, and, most<br>importantly, immune waning.<br>Moreover, several new data resources became available or were improved during the<br>pandomic requiring power unde

the same time, and, (4) modelling of age-dependent vacanties entering, and, and the improveding the improved during the pandemic requiring new or updated data models to be linked with the updated enidemiclogic model. We in Importantly, increased in the Moreover, several new data<br>pandemic requiring new or<br>epidemiologic model. We integ pandemic requiring new or updated data models to be linked with the updated<br>epidemiologic model. We integrated, for example, data on the progression of the vaccination<br>and booster campaigns per age group and considered res particular requiring new or up and an arrange in the under the under the updated<br>epidemiologic model. We integrated, for example, data on the progression of the vaccination<br>and booster campaigns per age group and considere epidemiologic model. The programs of the program is the vacant of the vacant and booster campaigns per age group and considered respective differences between German federal states. We collected and included external study German federal states. We collected and included external study data on vaccination efficacy, waning dynamics and booster efficacies as well as seropositivity studies. We also EFINING FERENCE CONTROLLER STATES. We consider the included and included the seconditivity studies. We also<br>efficacy, waning dynamics and booster efficacies as well as seropositivity studies. We also efficacy, waning dynamics and booster efficiency studies. We also the propositivity studies. We also the serop<br>. We also the series as well as series as well as seron to the series of the series of the series of the series It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

considered the heterogeneity of pandemic dynamics across states allowing estimating state-

facilitating our proposed full information approach. Finally, we improved our modelling architecture in order to speed<br>processing and calculations coping with the high-dimensional dat<br>facilitating our proposed full information approach. Finally, we improved the intertaining intrictuate in order to speed up and parameter space<br>facilitating our proposed full information approach.<br>Materials and methods processing and calculations contains a container the dimensional data and parameter space.<br> **Materials and methods**<br> *General approach* 

## Materials and methods

### General approach

We consider an input-output non-linear dynamical systems (IO-NLDS) originally proposed as time-discrete alternatives to pharmacokinetic and -dynamic differential equations models [2,3]. This class of models couples a set of dynamical input parameters such as external influences and factors with a set of outp [2,3]. This class of models couples a set of dynamical input parameters such as external influences and factors with a set of output parameters, i.e. observations by a hidden model structure to be learned (named *core mode* influences and factors with a set of output parameters, i.e. observations by a hidden model influences and factors with a set of output parameters, i.e. output about the set of structure to be learned (named *core model* in the following). This coupling represents a hybrid modelling concept, in which deterministi structure to be learned (named *tore model* in the following). This coupling represents a hybrid modelling concept, in which deterministic model equations reflecting our mechanistic understanding of the pandemic are combin moderstanding of the pandemic are combined with empirical relationships of state variables<br>and observational data called *data models* in the following. This represents a major feature of<br>our approach because it allows sep and observational data called *data models* in the following. This represents a major feature of our approach because it allows separating the tasks of epidemiologic model development and addressing data issues such as cor and observational data called *data models* in the following. This represents a major feature of<br>our approach because it allows separating the tasks of epidemiologic model development<br>and addressing data issues such as cor and addressing data issues such as corrections for incomplete or biased observational data prior to model parametrization. prior to model parametrization.<br>
Concepts and assumptions of the core model

# Concepts and assumptions of the core model

r<br>Concepts and assumptions of the co<br>Our core model is of SECIR  $\frac{1}{2}$ The core model is of SECIR type and consistent of several sub-models are<br>characterized by up to three different attributes namely age group, immune status (is),<br>including its waning after vaccination or infection events an characterized by up to three different attributes namely age group, immune status (is), including its waning after vaccination or infection events and virus variant ( $vv$ ).<br>More precisely, we considered the following catego including its waning after vaccination or infection events and virus variant ( $vv$ ).<br>More precisely, we considered the following categories of these features:

- Five age groups: 1-14 years, 15-34 years, 35-59 years, 60-79 years and  $\geq 80$  years
- Including its wannig after vaccination or infection events and virus variant (*vv*).<br>More precisely, we considered the following categories of these features:<br>• Five age groups: 1-14 years, 15-34 years, 35-59 years, 60-79 • Five age groups: 1-14 years, 15-34 years, 35-59 years, 60-79 years a<br>• Ten virus variants: WT (wild type), alpha, delta, omicron BA1, BA<br>with BQ.1, XBB, BA.2.86 and KP.3 •
	- with BQ.1, XBB, BA.2.86 and KP.3<br>
	 Four immune statuses: naïve due to absence of vaccinations or infections (S) or shortly after first vaccination (*Vac*o), highly protected by either recent vaccination TEN VIRUS VIRUS VARIATION (WILD TYPE), alpha, album, culturated y seem and status variables with BQ.1, XBB, BA.2.86 and KP.3<br>Four immune statuses: naïve due to absence of vaccinations or infections (S) or shortly after fi Four immune statuses: naïve du<br>shortly after first vaccination (*Va*<br>(*Vac*<sub>1</sub>) or recovery from a recent i<br>weakly protected (*Vac*<sub>3</sub>, *R*<sub>3</sub>), see Tal • Four immune statuses: naïve due to absence of vaccinations or infections (*S*) or shortly after first vaccination (*Vaco*), highly protected by either recent vaccination (*Vac*<sub>1</sub>) or recovery from a recent infection ( (*Vaci*) or recovery from a recent infection  $(R_1)$ , moderately protected (*Vac<sub>2</sub>*,  $R_2$ ), and weakly protected (*Vac<sub>3</sub>*,  $R_3$ ), see Table 1.<br>ume four vaccination statuses to account for the fact that protection again

(*Vac1*) or recovery from a recent infection (*K1*), moderately protected (*Vac2*, *K2*), and<br>weakly protected (*Vac3*, *R3*), see Table 1.<br>ume four vaccination statuses to account for the fact that protection against inf weakly protected (*Vacs*, *Ks*), see Table 1.<br>ume four vaccination statuses to accour<br>mplete and wanes much faster than pr<br>AA8 in Appendix A). Assignment of is incomplete and wanes much faster than protection against critical disease courses (see Table AA8 in Appendix A). Assignment of attributes to compartments is modelled as multidimensional parameter arrays (tensors). Table AA8 in Appendix A). Assignment of attributes to compartments is modelled as Table AA8 in Appendix A). Assignment of attributes to compartments is modelled as<br>multidimensional parameter arrays (tensors). multidimensional parameter arrays (tensors).

We distinguish three major compartment groups by their assigned attributes: (1) Infectable subjects without previous infection events  $(Sc, Vac)$  carry attribute age, (2) Infectable subjects with previous infection events  $(R$ with previous infection events ( $R$ ) carry attributes age, previous virus variant (one of the ten variants: WT; alpha, delta BA1, BA2, BA5, BA.2.75/ BQ.1, XBB, BA.2.86, KP.3), immune status prior to previous infection (na variants: WT; alpha, delta BA1, BA2, BA5, BA.2.75/ BQ.1, XBB, BA.2.86, KP.3), immune status prior to previous infection (naïve, highly, moderately or weakly protected), and, (3) Infected subjects (*E*, *I*) with attribute prior to previous infection (naïve, highly, moderately or weakly protected), and, (3) Infected<br>subjects (*E*, *I*) with attributes age, virus variant and immune status prior to infection. For the<br>latter, we assume that on subjects (*E*, *I*) with attributes age, virus variant and immune status prior to infection. For the latter, we assume that only *I* is contagious. Compartments *H* and *C* representing patients admitted to hospital ward subjects (E, I) with attributes age, virus variant and immune status prior to infection. For the<br>latter, we assume that only I is contagious. Compartments H and C representing patients<br>admitted to hospital ward or ICU are admitted to hospital ward or ICU are only count compartments. They have the same<br>attributes of their originating compartment I and represent a second hidden layer of our<br>model, which is later connected to respective observ attributes of their originating compartment  $I$  and represent a second hidden layer of our model, which is later connected to respective observational data.<br>In more detail, we make the following assumptions. attributes of their originating compartment *I* and represent a second muderi layer of our<br>model, which is later connected to respective observational data.<br>In more detail, we make the following assumptions.<br>1. Infected co

- model, which is later connected to respect to respect the following assumptions.<br>1. Infected compartments are those carrying a specific virus compartments E, I, H, and C. I. Infected compartments are those carrying a s<br>compartments E, I, H, and C.<br>2. The latent state  $E$  comprises infected but non-<br>state between becoming infected and becomi
	-
	- 1. Interest compartments E, I, H, and C.<br>
	2. The latent state E comprises infected but non-contagious subjects. This is the transient<br>
	3. To model time delays in transitions, we frequently divided compartments into sub-<br>
	1 The latent state E comprises in<br>The latent state E comprises in<br>state between becoming infec<br>To model time delays in trar<br>compartments with first ord 2. The latent state E comprises infected but non-contagious subjects. This is the transient<br>state between becoming infected and becoming contagious.<br>3. To model time delays in transitions, we frequently divided compartment To model time delays in transitions, we frequently divided<br>compartments with first order transitions. This approace<br>pharmacological models [4]. It was shown that this appr<br>distributed transit times [5]. compartments with first order transitions. This approach is extensively used in pharmacological models [4]. It was shown that this approach resembles Gamma-<br>distributed transit times [5]. pharmacological models [4]. It was shown that this approach resembles Gamma-<br>distributed transit times [5].<br>The infected state *I* is the only state assumed to be contagious and is divided into four<br>sequential compartment
	- which patients can proceed either to  $D$  (death compartment, representing deaths due The infected state  $I$  is the onl<br>sequential compartments. T<br>which patients can proceed<br>to COVID-19) or to  $I_3$ . Finall 4. The infected state I is the only state assumed to be contaglous and is divided into four sequential compartments. There is a single branching for the compartment  $I_2$ , from which patients can proceed either to D (deat sequential compartments. There is a single branching for the compartment I2, from<br>which patients can proceed either to D (death compartment, representing deaths due<br>to COVID-19) or to I<sub>3</sub>. Finally, the efflux of I<sub>4</sub> ente to COVID-19) or to I<sub>3</sub>. Finally, the efflux of I<sub>4</sub> enters R<sub>1</sub> representing resolved disease courses.<br>All sub-compartments of I contribute to new infections, depending on age, virus variant, and immune status of target
	-
	- to COVID-19) or to Is. Finally, the efflux of I4 enters RT representing resolved disease<br>courses.<br>All sub-compartments of I contribute to new infections, depending on age, virus<br>variant, and immune status of target subject All sub-<br>variant, a<br>The com<br>treatmen<br>fluxes bu S. All sub-compariments of T commute to new infections, depending on age, virus<br>variant, and immune status of target subjects.<br>6. The compartment  $I_2$  is considered the source of severe disease outcomes comprising<br>treatm The compartment  $I_2$  is considered the source<br>treatment at hospital wards  $H$  or ICU (C). Th<br>fluxes but as counting respective bed occupan<br>The compartment  $H$  represent disease states re<br>that these patients are not infec
	- Free compariment 12 is considered the source of severe disease outcomes comprising<br>treatment at hospital wards  $H$  or ICU (C). These contributions are not modelled by<br>fluxes but as counting respective bed occupancies.<br>7. treatment at hospital wards H of ICU (C). These contributions are not modelled by<br>fluxes but as counting respective bed occupancies.<br>The compartment H represent disease states requiring hospital ward care. We assume<br>that The compartment *H* represent disease states require<br>that these patients are not infectious due to isola<br>into three sub-compartments, *H<sub>1</sub>*, *H<sub>2</sub>*, and *H<sub>3</sub>* to<br>hospital ward bed occupancies. *Rhosp* counts reso<br>ward st The compariment H represent disease states requiring hospital ward care. We assume<br>that these patients are not infectious due to isolation. The compartment is divided<br>into three sub-compartments,  $H_1$ ,  $H_2$ , and  $H_3$  t into three sub-compartments,  $H_1$ ,  $H_2$ , and  $H_3$  to allow comparisons with data of hospital ward bed occupancies. *Rhosp* counts resolved disease courses after hospital ward station care.<br>The compartment C represents
- into three sub-compartments, *TH*, *TL*, and *T*<sub>3</sub> to allow comparisons with data of hospital ward bed occupancies. *Rhosp* counts resolved disease courses after hospital ward station care.<br>The compartment *C* represents hospital ward bed occupancies. *Rhosp* counts resolved disease courses after hospital<br>ward station care.<br>The compartment C represents critical disease states requiring intensive care. Again,<br>we assume that these patients a The compartment<br>The compartment<br>we assume that the<br>sub-compartments<br>with data of ICU I 8. The compartment C represents critical disease states requiring intensive care. Again, we assume that these patients are not infectious due to isolation. In analogy to the compartment of hospital ward treatment, this com compartment of hospital ward treatment, this compartment is also divided into three<br>sub-compartments to mimic disease courses allowing comparing the compartment<br>with data of ICU bed occupancies. *Ricu* counts resolved dise sub-compartments to mimic disease courses allowing comparing the compartment<br>with data of ICU bed occupancies. *Ricu* counts resolved disease courses after critical<br>state to model cumulative data.<br>Basic qualitative propert with data of ICU bed occupancies. Ricu counts resolved disease courses after critical

with data of ICU bed occupancies. Ricu counts resolved disease courses after critical<br>state to model cumulative data.<br>aalitative properties of infectable compartments assigned with different immune<br>s are provided in Table state to model cumulations in<br>
ualitative properties of infectable<br>
s are provided in Table 1. Respect  $\frac{1}{2}$  $B = 4\pi$  and  $\frac{1}{2}$  and  $\frac{1}{2}$  and  $\frac{1}{2}$  and  $\frac{1}{2}$  are  $\frac{1}{2}$  and  $\frac{1}{2}$  are  $\frac{1}{2}$  and  $\frac{1}{2}$  and  $\frac{1}{2}$  are  $\frac{1}{2}$  and  $\frac{1}{2}$  are  $\frac{1}{2}$  and  $\frac{1}{2}$  are  $\frac{1}{2}$  and  $\frac{1}{2}$  ar status estatuses are provided in Table 1. Respective transitions are displayed in Figure 1. More 1. Mo

medRxiv preprint doi: [https://doi.org/10.1101/2024.11.11.24317088;](https://doi.org/10.1101/2024.11.11.24317088) this version posted November 11, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

details of model compartments and their properties are provided in Table AA1 of Appendix<br>A.<br>Table 1. Qualitative properties of the sub-models reflecting different immune statuses. These

A.<br>Tal<br>pro  $\begin{bmatrix} 1 \\ 1 \\ 1 \end{bmatrix}$ properties mirror the immune memory induced by vaccination or last infection event.



 $\frac{1}{1}$  $\begin{array}{c} \n\lambda \quad \text{if} \quad \lambda \quad \text{if} \quad \lambda$ All model assumptions are translated into a difference equation system (see Appendix **B**). The mathematical structure is that of an Input-Output Non-linear System as depicted in Figure 1. Relationships between immune statu in Figure 1. Relationships between immune statuses obtained by vaccination or a previous infection event and possible disease courses are displayed at Figure 2. Model parameters are explained in the **Appendix A**. parameters are explained in the Appendix A.

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .



Figure 1: General scheme of our epidemiologic model. Our epidemiologic SECIR model is embedded as a hidden layer into an IO-NLDS. Respective equations are provided in Error! Reference source not found.B. Compartments are grouped according to whether they correspond to infectable (green) or infected (blue) subjects. Attributes of sub-models (i.e.  $age$ ,  $vv$  and and is) are not displayed for simplicity. The infectable compartments without previous infection events  $(S, Vac)$  only depend on age while the other compartments depend on age, virus variant, and if applicable, on the last infection event. The input layer consists of external factors acting on the epidemic such as vaccination campaigns or parameter changes due to changes in testing policy, and non-pharamceutical interventions. The output layer is derived from respective hidden layers via stochastic relationships (data models, see later). The output layer is compared with real-world data. The number of hospital  $(H)$  and ICU  $(C)$ . admissions are described as additional hidden layers counting these events and describing dynamics of bed occupancies. dynamics of bed occupancies.

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .



Figure 2. General scheme of the relationships between immune status, infection and severity of disease course. Probability and course of infection depends on the current immune status. Three immune statuses are distinguished: (1) immune-naïve and freshly vaccinated subjects (left), (2) Subjects with recent vaccination or freshly recovered subjects (middle) and (3) subjects with waned immune protection (right). Transition probabilities  $\overrightarrow{p}$  as (Z, a) depend on the current immune status and the infecting variant a. Stronger risks are illustrated by broader arrows.  $p$ <sub>is</sub>( $\mathbf{z}, \boldsymbol{u}$ ) depend on the current immune status and the infecting variant *a.* Stronger risks are illustrated by broader arrows. illustrated by broader arrows.

#### $\overline{a}$ Input Layer

We here describe the structure of the input layer of our IO-NLDS. This layer is designed to model the impact of external factors acting on the epidemiologic dynamics such as changing infection rates due to non-pharmaceutical interventions, vaccination and booster campaigns and changing testing policies. Effectively, these input functions dynamically affect Effectively, these input functions dynamically affect parameters of the hidden layer containing the epidemiologic model. We describe these different external factors in the following. Respective parameters are described in table 4. different external factors in the following. Respectively, and the following parameters are described in table 4.4.

Dynamical infection rate: We define a step function  $b_1$  as time-dependent input parameter modifying the rate of infections. To identify time points of steps, we used a data-driven approach based on Bayesian Information Criterion (BIC) informed by time points of governmental changes in non-pharmaceutical counter-measures in Germany, changing testing policies as well as events with significant impact on epidemiological dynamics such as holidays or sudden outbreaks [2]. Details can be found in **Error! Reference source not** as holidays or sudden outbreaks  $[2]$ . Details can be found in Error: **Reference source not**<br>found.. **found.**.<br>Daily testing and number of undetected cases (estimation of dark figure): It is well-known that

reported numbers of infections are largely underestimated and that this bias is time-<br>dependent during the pandemic. We estimate the dark-figure (DF) based on calibration analyses of seropositivity-data and near-representative systematic testing from the analyses of surpresently man near-representative systematic terting from the SentiSurv study (See Error! Reference source not found. Respective time-dependent

epidemiologic model compartments.<br>Vaccination and booster campaigns: Numbers of applied vaccination and booster doses are<br>available from the German Robert-Koch institute on a daily scale and per age-group and<br>federal state F<br>Vaccination and booster campaigns: N<br>available from the German Robert-K<br>federal state. We distribute respecti<br>according to their relative size. vactination and booster campaigns. Islambers of applied vaccination and booster doses are<br>available from the German Robert-Koch institute on a daily scale and per age-group and<br>federal state. We distribute respective vacci available from the German Robert-Koch institute on a daily scale and per age-group and<br>federal state. We distribute respective vaccination rates over eligible model compartments<br>according to their relative size.<br>Output Lay federal state in the distribute respective vacancies over eligible distribute respectively according to their relative size.<br>
Output Layer, Data and Parameter Fitting<br>
Unknown parameters of the model are determined by para

#### Output Layer, Data and Parameter Fitting

o<br>O*utput Layer, Data and Paramete*<br>Unknown parameters of the m<br>compartments of our hidden la U number of our hidden layer epidemiologic model are coupled with observational data<br>via the output layer of our IO-NLDS using appropriate (stochastic) link functions called *data-models*. We here present these data, respe via the output layer of our IO-NLDS using appropriate (stochastic) link functions called *data-models*. We here present these data, respective data-models and objective functions in the following.<br>We fit our model to age-

models. We here present these data, respective data-models and objective functions in the following.<br>We fit our model to age- and federal state-specific time series data of reported numbers of infections  $I_M$ , occupation models. We here present these data, respective data-models and objective functions in the following.<br>We fit our model to age- and federal state-specific time series data of reported numbers of<br>infections *I<sub>M</sub>*, occupation We fit our<br>infections<br>representir<br>dynamics.<br>Data sourc infections *I<sub>M</sub>*, occupation of hospital stations  $N_M$ , occupation of ICU beds  $C_M$  and deaths  $D_M$ <br>representing the output layer of our IO-NLDS model. Moreover, we fitted data of the variant<br>dynamics.<br>Data sources of in

infections *IM*, occupation of hospital stations *NM*, occupation of ICU beds CM and deaths DM<br>representing the output layer of our IO-NLDS model. Moreover, we fitted data of the variant<br>dynamics.<br>Data sources of infection representing the output layer of our IO-NLD interferent respectively. The variation dynamics.<br>Data sources of infections, normal ward admissions and deaths were publicly available from<br>the Robert-Koch-Institute (RKI). For *)*<br>the Robert<br>September<br>German I1<br>Interdiszip The Robert-Koch-Institute (RKI). For our modelling, we used data from March 4<sup>th</sup>, 2020 to September 12<sup>th</sup>, 2024. Number of critical cases, i.e. ICU admissions were retrieved from the German Interdisciplinary Association September 12<sup>th</sup>, 2024. Number of critical cases, i.e. ICU admissions were retrieved from the German Interdisciplinary Association of Intensive and Emergency Medicine (Deutsche Interdisciplinary Association of Intensive an September 12<sup>th</sup>, 2024. Number of critical cases, i.e. ICO admissions were retrieved from the<br>German Interdisciplinary Association of Intensive and Emergency Medicine (Deutsche<br>Interdisziplinare Vereinigung für Intensiv- u Interdisziplinare Vereinigung für Intensiv- und Notfallmedizin e.V. — DIVI) for the time window March 25<sup>th</sup>, 2020 to September 12<sup>th</sup>, 2024. Time points in proximity to Christmas and the turn of the year 2020/21 (i.e. De Interdisciplinary 2020 to September 12<sup>th</sup>, 2024. Time points in proximity to Christmas and the turn of the year 2020/21 (i.e. December 19<sup>th</sup>, 2020 to January 19<sup>th</sup>, 2021) were heavily biased and therefore discarded duri

window March 25<sup>th</sup>, 2020 to September 12<sup>th</sup>, 2024. Time points in proximity to Christinas and<br>the turn of the year 2020/21 (i.e. December 19<sup>th</sup>, 2020 to January 19<sup>th</sup>, 2021) were heavily<br>biased and therefore discarded the turn of the year 2020/21 (i.e. December 19<sup>th</sup>, 2020 to January 19<sup>th</sup>, 2021) were heavily<br>biased and therefore discarded during parameter fitting.<br>Despite this fact, considered data are still largely biased, i.e. cann bespite this fact, considered data are still largely biased,<br>parameters of our epidemiologic model. This was addres<br>steps and data models aiming at removing major biases o parameters of our epidemiologic model. This was addressed by the following pre-processing<br>steps and data models aiming at removing major biases of<br>Infected cases: We first smoothed reported numbers of infections with a sli

parameters and data models aiming at removing major biases of<br>Infected cases: We first smoothed reported numbers of infections with a sliding window approach of<br>seven days centered at the time point of interest to remove t steps and data models and day are models and the proof infected cases: We first smoothed reported numbers of infections<br>seven days centered at the time point of interest to remove the str<br>We assume that these numbers corre  $\frac{1}{2}$ To project true infection numbers, we estimate the time-dependent dark figure as explained above. We<br>further account for delays in the reporting of case numbers by introducing a log-normally<br>distributed delay time as expla seven days centered at the time point of interest to remove the strong weekly periodicity of the data. We assume that these numbers correspond to a certain percentage of registered symptomatic patients.

further account for delays in the reporting of case numbers by introducing a log-normally<br>distributed delay time as explained in Error! Reference source not found..<br>Deaths and hospital ward admissions: Deaths and hospital distributed delay time as explained in Error! Reference source not found..<br>Deaths and hospital ward admissions: Deaths and hospital ward admissions were reported a<br>daily scale by the RKI since the beginning and end of Marc Deaths and hospital ward admissions: Deaths and hospital ward admissions<br>daily scale by the RKI since the beginning and end of March 2020<br>However, due to data privacy, RKI did not provide exact dates of death<br>admissions. R Deaths and hospital ward admissions. Deaths and hospital ward admissions were reported at a<br>daily scale by the RKI since the beginning and end of March 2020 [22], respectively.<br>However, due to data privacy, RKI did not pro However, due to data privacy, RKI did not provide exact dates of deaths or hospital ward<br>admissions. Rather than this, reported dates of death and hospitalized patients correspond to<br>the dates of reported infections of the admissions. Rather than this, reported dates of death and hospitalized patients correspond to the dates of reported infections of these patients. We aimed to remove the resulting reporting delay by assuming log-normally di and the dates of reported infections of these patients. We aimed to remove the resulting reporting<br>delay by assuming log-normally distributed delay times where the expected delay time is<br>derived from the respective transit delay by assuming log-normally distributed delay times where the expected delay time is<br>derived from the respective transit times of our model. Details can be found in Error!<br>Reference source not found..<br>**Critical cases:**

derived from the respective transit times of our model. Details can be found in Error!<br>Reference source not found..<br>Critical cases: Number of critical COVID-19 cases (DIVI reported ICU) was available since<br>the end of March Reference source not found..<br>Critical cases: Number of critical COVID-19 cases (DIVI reported ICU) was available since<br>the end of March 2020 [21]. We assumed that these data are complete since April 16<sup>th</sup>, 2020<br>when repor **Critical cases:** Number of critic<br>**Critical cases:** Number of critic<br>the end of March 2020 [21]. We<br>when reporting became manda the end of March 2020 [21]. We assumed that these data are complete since April  $16<sup>th</sup>$ , 2020 when reporting became mandatory by law in Germany. Earlier data were extrapolated from when reporting became mandatory by law in Germany. Earlier data were extrapolated from  $\mathbf{r}$  the number of reporting hospitals using the total number of ICU beds available according to the reported ICU capacity at 2018. These estimates are coupled with the sum of critical subcompartments  $C_i$  ( $i = 1,2,3$ ) of our

The latter summarizes BA4 and 5  $[23]$ . Entry of new variants is modeled by an Frequency of variants: We consider ten virus variants constituting major waves in Germany, 1<br>1<br>1<br>1 namely WT, alpha, delta, omicron BA1, BA2, BA5, BA.2.75/ BQ.1, XBB, BA.2.86 and KP.3. The latter summarizes BA4 and 5 [23]. Entry of new variants is modeled by an instantaneous influx of infected subjects into the compartments E and I [24]. Respective parameters are estimated separately for each federal sta instantaneous influx of infected subjects into the compartments E and I [24]. Respective parameters are estimated separately for each federal state. For the purpose of parameter fitting, we also consider data of variant fr parameters are estimated separately for each federal state. For the purpose of parameter fitting, we also consider data of variant frequencies available for Germany taken from public reports of the RKI [23]. Details can be fitting, we also consider data of variant frequencies available for Germany taken from public reports of the RKI [23]. Details can be found in Error! Reference source not found., formula

#### Parametrization approach

We carefully searched the literature to establish ranges for mechanistic model parameters. 、<br>*Parameti*<br>We care<br>We con  $\begin{array}{c} 1 \\ 1 \\ 1 \end{array}$ We considered two alternatives for parameter estimation: usage of these data as prior information for a Bayesian approach (implemented in our earlier work [2]) or set the parameters from the literature parameters as fixed information for a Bayesian approach (implemented in our earlier work [2]) or set the<br>parameters from the literature parameters as fixed values (Table A2, justification see<br>Appendix F). Comparison of goodness of fits favour parameters from the literature parameters as fixed values (Table A2, justification see<br>Appendix F). Comparison of goodness of fits favoured the second alternative. Parameter<br>estimation is achieved via likelihood optimizati **Appendix F**). Comparison of goodness of fits favoured the second alternative. Parameter estimation is achieved via likelihood optimization. The likelihood is constructed using similar principles as reported previously [25 Appendix F). Comparison of goodness of fits favoured the second anemative. I arameter<br>estimation is achieved via likelihood optimization. The likelihood is constructed using<br>similar principles as reported previously [25]. estimate the plane of the difference of plane and the likelihood consists of three major<br>parts, namely a penalty term to ensure that model parameters are within prescribed ranges,<br>as well as penalties for the variability o parts, namely a penalty term for ensure that model parameters are within prescribed ranges, as well as penalties for the variability of parameters across federal states as explained in **Appendix** E. Penalization of variabi parts, namely as well as penalties for the variability of parameters across federal states as explained in **Appendix E**. Penalization of variability of parameters across federal states is a sort of pruning to avoid overfit Appendix E. Penalization of variability of parameters across federal states is a sort of pruning to avoid overfitting [26]. We follow a full-information approach intended to use all data collected during the epidemic as ex Appendix E. Fenalization of variability of parameters across federal states is a sort of<br>pruning to avoid overfitting [26]. We follow a full-information approach intended to use all<br>data collected during the epidemic as ex pruning to all the treating  $p$ -rights clear in the intertimental properties in the method.<br>
data collected during the epidemic as explained in Error! Reference source not found.<br>
Consequently, our parametrization approach data conected during the epidemic as explained in Error! Reference source not found..<br>Consequently, our parametrization approach is intended to describe complete dynamics of<br>the epidemic in Germany and its federal states i The epidemic in Germany and its federal states in the time period covered by the data (Error!<br>Reference source not found. and Error! Reference source not found.).<br>Likelihood optimization is achieved using a variant of the the epidemic in Germany and its federal states in the time period covered by the data (Error:<br>Reference source not found, and Error! Reference source not found.).<br>Likelihood optimization is achieved using a variant of the

Reference source not found. and Error: Reference source not found.).<br>Likelihood optimization is achieved using a variant of the Hooke-Jeeve<br>This is a zero-order algorithm, which does not require expensive calcu<br>of the fitn This is a zero-order algorithm, which does not require expensive calculations of derivation for the fitness function to be optimized. In brief, the method relies on iterated updat current fitness values and respective para - < < i I The fitness function to be optimized. In brief, the method relies on iterated updates of current fitness values and respective parameter settings by comparisons with fitness values in the neighborhood of the current parame current fitness values and respective parameter settings by comparisons with fitness values<br>in the neighborhood of the current parameter settings separately for all coordinates.<br>Perturbation sizes at each dimension are ada current finally burned and respective parameter settings separately for all coordinates.<br>Perturbation sizes at each dimension are adapted in dependence on the result of the previous<br>iteration step, i.e. a perturbation in t Forturbation sizes at each dimension are adapted in dependence on the result of the previous<br>iteration step, i.e. a perturbation in the s-th dimension becomes larger if a better fitness value<br>was found for this dimension i Perturbation step, i.e. a perturbation in the s-th dimension becomes larger if a better fitness value was found for this dimension in the previous iteration. Otherwise, it is reduced in the next step, provided that it does was found for this dimension in the previous iteration. Otherwise, it is reduced in the next<br>step, provided that it does not drop below a specified lower limit. An exception are<br>parameters related to the time of entry of n step, provided that it does not drop below a specified lower limit. An exception are parameters related to the time of entry of new variants for which we used a constant step size of one day in order to stabilize converge parameters related to the time of entry of new variants for which we used a constant step size of one day in order to stabilize convergence since these parameters are highly sensitive.<br>The algorithm stops if the last four parameters relative to the time of the time of the time of size of one day in order to stabilize convergence since these parameters are highly sensitive.<br>The algorithm stops if the last four steps did not provide a relati

The algorithm stops if the last four steps did not provide a relative improvement of the fitness function of more than a specified tolerance parameter  $\delta_{tol}$ .<br>Identifiability of parameters was checked using profile likel The algorithm stop in the last four stoppe into the protein a relative inperfonment<br>fitness function of more than a specified tolerance parameter  $\delta_{tot}$ .<br>Identifiability of parameters was checked using profile likelihood fitness function of more than a specified tolerance parameter  $\delta \omega$ .<br>Identifiability of parameters was checked using profile likelihoo<br>explained in the supplement. Dynamical parameters were deterr<br>number of these steps wa I < r Explained in the supplement. Dynamical parameters were determined by step functions. The number of these steps was determined based on pre-described events or empirically. The Bayesian Information Criterion was applied to explained in the supplement. Dynamical parameters were determined by step functions and<br>number of these steps was determined based on pre-described events or empirically. The<br>Bayesian Information Criterion was applied to p Bayesian Information Criterion was applied to penalize the number of steps. Bayesian Information Criterion was applied to penalize the number of steps.

י<br>}<br>}<br>1 profile likelihood of a parameter is obtained when optimizing the likelihood conditional to<br>this parameter: we fix different values of the given parameter and reoptimize all other by<br>maximizing the likelihood. We obtain th profile and anti-term is a parameter values of the given parameter and reoptimize all other by maximizing the likelihood. We obtain thus functional dependence of the likelihood function on fixed values of a given parameter The product of the likelihood. We obtain thus functional dependence of the likelihood function<br>on fixed values of a given parameter. If the fixation of these parameters to the known from<br>the literature values does not lead on fixed values of a given parameter. If the fixation of these parameters to the known from<br>the literature values does not lead to improve of the likelihood compared to the case of their<br>estimation, we consider this param the literature values does not lead to improve of the likelihood compared to the case of their<br>estimation, we consider this parameter as redundant. However, this technique is very time<br>consuming. Thus, we applied it to de estimation, we consider this parameter as redundant. However, this technique is very time<br>consuming. Thus, we applied it to determine identifiability of only few system parameters:<br>the contact matrix terms, relative initi consuming. Thus, we applied it to determine identifiability of only few system parameters:<br>the contact matrix terms, relative initial influxes *rinflux<sup>age</sup>* and parameters  $r_1$ ,  $r_3$ ,  $r_5$ ,  $r_6$ ,<br> $r_7$  and  $r_9$ , for the contact matrix terms, relative initial influxes *rinflux<sup>age</sup>* and parameters  $r_1$ ,  $r_3$ ,  $r_5$ ,  $r_6$ ,  $r_7$  and  $r_9$ , for which reliable prior values are known from the literature.<br>Implementation  $r_7$  and  $r_9$ , for which reliable prior values are known from the literature.

#### Implementation

 $\epsilon$  and parameters  $r_1$ ,  $r_3$ ,  $r_5$ ,  $r_6$ , eliterature.<br>dures are implemented in the vavailable functions are called. *and i<sub>9</sub>*, for which reliable prior values are known from the inerature.<br>
Implementation<br>
The model and respective parameter estimation procedures are is<br>
statistical software package R from which external publicly avail  $\begin{array}{c} \n1 \\ \n1 \n\end{array}$ The model's equation solver is implemented as C++ routine and called from R code using the Rcpp package.<br>The model's equation solver is implemented as C++ routine and called from R code using the Rcpp package. The model's equation solver is implemented as  $C^{++}$  routine and called from R code using the Rcpp package.

#### Results

The model of quantuments is implemented as C++ routine and called from analysine<br>Results<br>We aim to explain the dynamics of the COVID-19 pandemic regarding infected subjects,<br>hospital ward and ICU occupation, deaths and var External processes<br>Results<br>We aim to exp<br>hotween March hospital ward and ICU occupation, deaths and variant frequency for the entire time period<br>between March 4th, 2020 up to September 12th, 2024 for Germany and its federal states. We<br>first present the results of our parameter hospital ward and Herveen March 4th, 2020 up to September 12th, 2024 for Germany and its federal states. We first present the results of our parameter fittings. We then show the resulting agreement of model and data for Ge first present the results of our parameter fittings. We then show the resulting agreement of model and data for Germany and its federal states and discuss the dynamics of immune statuses. Based on the observation of largel firm of our present and data for Germany and its federal states and discuss the dynamics of immune<br>statuses. Based on the observation of largely deviating dynamics between federal states, we<br>analyse respective heterogeneit statuses. Based on the observation of largely deviating dynamics between federal states, we analyse respective heterogeneity in data and parameters in more detail. Finally, we present a number of validated model prediction analyse respective heterogeneity in data and parameters in more detail. Finally, we present a number of validated model predictions. mumber of validated model predictions.<br>
Parameter fitting and identifiability.<br>
Most of the model parameters were obtained by fitting the predictions of the model to

#### Parameter fitting and identifiability.

Most of the model parameters were obtained by fitting the predictions of the model to available data of infection dynamics, hospital burden, deaths and variant frequencies.  $\begin{array}{c} \n1 \n1 \n2 \n\end{array}$ available data of infection dynamics, hospital burden, deaths and variant frequencies.<br>Parameters were set constant based on profile likelihood examination. Overfitting was<br>further controlled by a BIC-based model selection Parameters were set constant based on profile likelihood examination. Overfitting was<br>further controlled by a BIC-based model selection process (see methods).<br>Likelihood profiling showed that most of the mechanistic param

Further controlled by a BIC-based model selection process (see methods).<br>Likelihood profiling showed that most of the mechanistic parameters of the SECIR model<br>such as the transition rates,  $r_3$ ,  $r_5$ ,  $r_6$  and  $r_7$ , Likelihood profiling showed that most of the mechanistic parameters of such as the transition rates,  $r_3$ ,  $r_5$ ,  $r_6$  and  $r_7$ , could be fixed to the values, studies (Error! Reference source not found.). The likelihoo such as the transition rates,  $r_3$ ,  $r_5$ ,  $r_6$  and  $r_7$ , could be fixed to the values, derived from other studies (Error! Reference source not found.). The likelihood was only sensitive to parameters  $r_1$  representin studies (Error! Reference source not found.). The likelihood was only sensitive to parameters  $r_1$  representing the basic infection rate and  $r_9$  representing the hospitalization rate.<br>The results of parameter estimates  $r_1$  representing the basic infection rate and  $r_9$  representing the hospitalization rate.<br>The results of parameter estimates can be found in **Appendix K** and **Appendix L**.

#### Comparison of model predictions and observed data for Germany and its federal states

Throughout the pandemic, we observed a good agreement of modelled state variables and The results of parameter estimates can be found in Appendix K and Appendix L.<br>Comparison of model predictions and observed data for Germany and its federal states<br>Throughout the pandemic, we observed a good agreement of mo their linked output layers representing the data given the underlying data model. Agreement<br>was uniform for the five considered age groups (**Figure 3** upper panel) as well as for all 16<br>federal states (Error! Reference sou was uniform for the five considered age groups (Figure 3 upper panel) as well as for all 16 federal states (Error! Reference source not found. and Error! Reference source not found.). federal states (Error! Reference source not found. and Error! Reference source not found.).

The model is also in good agreement with the dynamics of virus variant frequencies (Figure 3 lower panel) thereby effectively separating the impact of the variant on the transmission dynamics from other reasons of differin

3 lower panel) thereby effectively separating the impact of the variant on the transmission<br>dynamics from other reasons of differing infectivities such as contact behavior or immunity<br>and its waning.<br>We account for tempora dynamics from other reasons and its waning.<br>We account for temporarily differing unreported cases specific for age groups and federal<br>counties by estimating a time-variant dark figure based on the reported percentage of<br>po and its waning.<br>We account for temporarily differing unreported cases specific for age groups and federal<br>counties by estimating a time-variant dark figure based on the reported percentage of<br>positive tests and seroprevale counties by estimating a time-variant dark figure based on the reported percentage of<br>positive tests and seroprevalence data. It revealed that the DF is subject to considerable<br>changes in between 50% and 150% unreported i positive tests and seroprevalence data. It revealed that the DF is subject to considerable changes in between 50% and 150% unreported infections compared to reported infections for Germany and the modelled time period. DF present their and serige tests and 150% unreported infections compared to reported infections for Germany and the modelled time period. DF was even larger for some of the federal states (see Appendix G for details).<br>Tempor Cortuing the state of and 150% and 150% and 150% and 150% unreported infections (see Appendix G for details).<br>Temporal changes of infectivity not explained by virus variants, dynamics of the dark figure<br>and dynamics of imm

Gee Appendix G for details).<br>Temporal changes of infectivity not explained by virus variants, dynamics of the dark figure<br>and dynamics of immune statuses of subjects is attributed to a stepwise dynamic change of<br>transmissi (see Appendix G for details).<br>Temporal changes of infectivi<br>and dynamics of immune sta<br>transmission parameter b1 (F<br>contact inhibition at different and dynamics of immune statuses of subjects is attributed to a stepwise dynamic change of<br>transmission parameter b1 (Figure 3 middle panel). This parameter reflects the strength of<br>contact inhibition at different phases of transmission parameter b1 (**Figure 3** middle panel). This parameter reflects the strength of contact inhibition at different phases of the pandemic due to NPI or changes in individual contact behaviour, e.g. due to holiday contact inhibition at different phases of the pandemic due to NPI or changes in individual contact behaviour, e.g. due to holidays or increased awareness. It is specific for age groups and federal states. contact behaviour, e.g. due to holidays or increased awareness. It is specific for age groups and federal states. It is specific for a group  $\frac{1}{2}$  is specific for age groups of a group specific for age groups of age groups of  $\frac{1}{2}$  is specific for age groups of  $\frac{1}{2}$  is specific for age groups of  $\frac{1$ 

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .



# $\overline{1}$

Figure 3: Agreement of model and data for Germany<br>We present the pandemic phase of Germany between March 4th, 2020 and September 12th, 2024 and compare observations (dashed lines) with the predictions of our IO-NLDS model (solid lines). Panel A shows good agreement of model and reported incidence of test positives for all age-groups considered. Panel B shows the dynamical parameter of relative infectivity  $b_1$  for the different age groups. Panel C shows the agreement of model and data of variant frequencies. At Panel D we present the model/data comparisons for age-specific dynamics of severe disease states, i.e. hospital ward and ICU occupation and cumulative deaths. Respective figures of the federal states are provided in the supplement.

Dynamics of immune states and their impact on severe disease courses Dynamics of immune states and their impact on severe disease courses

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

In our model, (re-)infection probability and susceptibility to severe courses of infection does not only depends on the attacking virus variant but also on the immune states of subjects including their immunization history. Here, we distinguish four different immune states:  $(1)$ the immunological naïve state (S/Vac0) with the highest susceptibility to infection and a severe course, (2) high and (3) moderate protection either due to vaccination (Vac1 and Vac2, respectively) or previous infection ( $R1$  and  $R2$ , respectively); and (4) low protection due to immune-waning (Vac3, R3). The dynamics of these modelled immune states for Germany is shown at Figure 4, and separately, for the federal states at Error! Reference source not shown at Figure 4, and separately, for the federal states at Error! Reference source not<br>found.. Age-group specific immune states are presented at Error! Reference source not found.. Age-group specific immune states are presented at Error! Reference source not



l, Figure 4 Estimated dynamics of modelled immune states for Germany: We present estimated dynamics of modelled different immune states for Germany (upper panel,  $S/Vac0 = \text{immune naïve}, \text{Vac3/R3} = \text{high risk}, \text{Vac2/R2} = \text{moderate risk}, \text{Vac1/R1} = \text{low risk}.$ For comparison, we present dynamics of the vaccination campaigns (middle panel) and cumulative number of infections (lower panel). cumulative number of infections (lower panel).

 $\frac{1}{1}$ These dynamics after the federal states, Error! Reference source not **Figure 3D** for Germany, and, separated for the federal states, Error! Reference source not Figure 3D for Germany, and, separated for the federal states, Error! Reference source not found..

### $\overline{a}$ The SARS-CoV-2 pandemic in Germany exhibited strong regional heterogeneity

Epidemic dynamics of federal states differed considerably, which could not be fully explained by difference in vaccination campaigns or age distribution. In this section, we analyse this heterogeneity in more detail by comparing respective data and model results. analyse this interegencely in more detail by comparing respective data and model results.

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

affecting the hospitalization (N), ICU (C), and death (D) compartments. We also assumed<br>state-specific parameters related to entries of new virus variants such as timing and initial<br>infection numbers. Moreover, dynamics o affection numbers. Moreover, dynamics of new virus variants such as timing and initial<br>infection numbers. Moreover, dynamics of the residual infectivity b<sub>1</sub> was assumed state-<br>specific. Selection of state-specific paramet infection numbers. Moreover, dynamics of the residual infectivity b<sub>1</sub> was assumed state-<br>specific. Selection of state-specific parameters was again based on BIC. Of note, it turned out<br>that no differences in viral propert specific. Selection of state-specific parameters was again based on BIC. Of note, it turned out that no differences in viral properties need to be assumed but that the majority of state-specific parameters correspond to po that no differences in viral properties need to be assumed but that the majority of state-<br>specific parameters correspond to population structure and pandemic management, which<br>indeed was heterogeneous across states. Durin indeed was heterogeneous across states. During fitting of state-specific parameters, we penalized deviations from the estimates obtained for Germany.

 $W_{\Omega}$  first analyzed the beterogrape in vith respect to infection numbers, deaths and test positivity (see Figure 5A-C). For example, Saxony had a death burden four times higher than penalized the heterogeneity with respect to infection<br>positivity (see Figure 5A-C). For example, Saxony had a death b<br>that of Schleswig Holstein. Testing policy varied across regions<br>in test positivity rates of up to 75%. the pandemic and between federal states. that of Schleswig Holstein. Testing policy varied across regions, as evidenced by differences in test positivity rates of up to 75%. Moreover, DF estimates different considerably during

in the pandemic and between federal states.<br>
Estimates of differences of the rates to develop a severe course are shown in **Figure XXX** and<br>
appeared to be plausible: Exemplarily, federal countries Saxony and Thuringia sho Estimates of differences of the rates to develop a severe course are shown in Figure XXX and appeared to be plausible: Exemplarily, federal countries Saxony and Thuringia show highest parameter estimates for transition rat Estimate of differences of differences of differences of the rates of plausing a show highest<br>parameter estimates for transition rates to the compartment D (death) in the oldest age group<br>80+ during the Delta and Omicron-B parameter estimates for transition rates to the compartment D (death) in the oldest age group<br>80+ during the Delta and Omicron-BA1 wave (**Figure 5D**). Correspondingly, both regions are<br>reported to have suffered from high e parameter estimates for transition rate comparation rate comparison rate comparison are solid and Omicron-BA1 wave (Figure 5D). Correspondingly, both regions are reported to have suffered from high excess mortality in the 80+ during the Delta and Omicron-BA1 wave (Figure 3D). Correspondingly, both regions are<br>reported to have suffered from high excess mortality in the elderly. Furthermore, death-<br>rates of Omicron variants are consistently l differences in infectivity, which are likely contact-intensity-driven, and differences in rates of Omicron variants are consistently lower than from previous variants (**Figure 5D**), again in line with the literature. According to our findings, disease dynamics vary across states primarily because of variations again in line with the literature. Hereining to our findings, include of variant introductions,<br>states primarily because of variations in the timing and magnitude of variant introductions,<br>differences in infectivity, which differences in infectivity, which are likely contact-intensity-driven, and differences in<br>severity parameters.<br>In Figure 6, we compared the between-state heterogeneity of infection dynamics with test<br>nocitivity and recidua

severity parameters.<br>In Figure 6, we compared the between-state heterogeneity of infection dynamics with test<br>positivity and residual infectivity estimates. We also estimated the number and timing of<br>successive introductio severity parameters.<br>In Figure 6, we compared the between-state heterogeneity of infection dynamics with test In Figure 1, we compare the convention the between-goldby to infection dynamics with test<br>positivity and residual infectivity estimates. We also estimated the number and timing of<br>successive introductions of SARS-CoV-2 vir successive introductions of SARS-CoV-2 virus variants in each federal state (Figure 7). successive introductions of SARS-Cov-2 virus variants in each federal state (Figure 7).

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .



Figure 5: Heterogeneity of the SARS-CoV-2 pandemics between federal countries and region-specific parametrisation of the model. Considerable between-state differences were observed regarding the course or the pandemic examplarily shown by the dynamics of infected subjects  $(A)$ , reported total number of deaths  $(B)$ , and probability of test-positivity reflectign testing policy  $(C)$ .

By estimating region-specific parameters as examplarily shown for the transfer rates from compartment infected I2 to compartment D dead the model can account for such differences (D). Consistently, federal countries Saxony and Thuringia, having suffered from high excess mortality in elderly in the alpha and delta wave, show highest parameter estimates in the oldest age group 80+. Regional specific parameter estimation for hospitalization rates and rates progressing to ICU are parameter estimation for the products and rates and rates progressing to ICU are<br>shown in Error! Reference source not found. and Error! Reference source not found., shown in Error! Reference source not found. **and** Error! Reference source not found.,<br>respectively respectively.

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .



Figure 6: Comparison of between-state heterogeneity of infection dynamics, testpositivity rates and residual infectivity. A) Reported test-positives per region **Example 31 The Test positivity C)** Estimated dynamical infecting rate b1. Time periods with increased heterogeneity between states are indicated with dashed rectangles. Here, heterogeneity is particularly high for both re B) test positivity C) Estimated dynamical infecting rate b1. Time periods with<br>increased heterogeneity between states are indicated with dashed rectangles. Here,<br>heterogeneity is particularly high for both reported testpos heterogeneity is particularly high for both reported testpositivity and residual infectivity b1.<br>infectivity b1.  $h = \frac{1}{2}$  is particularly high for both reported testpositivity and residual infectivity b1.  $\frac{1}{\sqrt{2}}$ 

#### It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .



 $\frac{1}{3}$ 

Figure 7: Region-specific model - estimation of the number and timepoints when successive<br>SARS-Cov-II virus variants were introduced in each federal country<br>Validated Model Predictions<br>We regularly used our model to predic Validated Model Predictions<br>We regularly used our model to predict scenarios of the future coupublished these predictions via our website (X<mark>XX</mark>). We here pres<br>predictions with the actual course of the pandemic in order to Validated Model Predictions<br>We regularly used our model to predict scenarios of the future course of the epidemic and

published these predictions via our website  $(XXX)$ . We here present comparisons of our<br>predictions with the actual course of the pandemic in order to validated our model.<br>*Comparsion of lockdowns December 2020 and November* predictions with the actual course of the pandemic in order to validated our model.<br>Comparsion of lockdowns December 2020 and November 2021 in Saxony: We used our model to<br>predict the impact of lockdown measures on residua predictions with the actual course of the pandemic in order to validated our model.<br>Comparsion of lockdowns December 2020 and November 2021 in Saxony: We used our model to<br>predict the impact of lockdown measures on residua Comparsion of lockdowns December 2020 and November 2021 in Saxony. We used our induct to<br>predict the impact of lockdown measures on residual infectivities of our age groups.<br>Comparing the lockdowns implemented in December predict the improvement in the inference the interest of 2020 and November 2021 in Saxony, it<br>revealed that similar reductions were achieved except for the youngest age group (Figure<br>8A). Indeed, this is plausible because revealed that similar reductions were achieved except for the youngest age group (Figure 8A). Indeed, this is plausible because schools and day care facilities remained open in the November 2021 lockdown compared to the De

8A). Indeed, this is plausible because schools and day care facilities remained open in the November 2021 lockdown compared to the December 2020 lockdown.<br>Based on these estimates, we predicted the further course of the pa November 2021 lockdown compared to the December 2020 lockdown.<br>Based on these estimates, we predicted the further course of the pandemic after initiating the<br>November 2021 lockdown and compared the results with a scenario Based on these estimates, we predicted the further course of the pandemic after initiating the Based on the Furthermannian Movember 2021 lockdown and compared the results with a scenario without lockdown measures (Figure 8B). We estimated that the lockdown might have saved a four-digit number of lifes. In addition, Movember 2021 2021 We estimated that the lockdown might have saved a four-digit number<br>of lifes. In addition, the lockdown might have roughly halved the peak in ICU bed<br>occupancy compared to the scenario without lockdown a measures (Figure 8B). We estimated that the lockdown might have saved a four-digit number<br>of lifes. In addition, the lockdown might have roughly halved the peak in ICU bed<br>occupancy compared to the scenario without lockdow occupancy compared to the scenario without lockdown assuming that these ICU bed<br>numbers could be supported. Finally, the further course of the pandemic closely resembles<br>our model prediction for several weeks. of the scenario compared to the summer of the scenario with numbers course and the finally resembles of the panel our model prediction for several weeks.

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .



Figure 8: Estimation of the impact of the lockdown measures introduced in November 2021 in Saxony and compared to the December 2020 lockdown. A) Model-based estimate in decline of infectivity after the introduction of more stringent lockdown measures at December 2020 and November 2021 as a threeweek average. While clear and comparable reductions in infectivities was estimated for the age-groups older than 14, the reduction for the younger age-group was much smaller in 2021 compared to 2020. This is plausible because schools and day care remained open in the 2021 lockdown. **B**) Modeled scenarios with and without introduction of lockdown. Without lockdown, the model predicted that infection numbers would increase until the end of December, and that the number of deaths would be increased in the order of >1,000 (https://www.health-atlas.de/documents/34). Model predictions are in reasonable agreement to the actual data. We used data from 2020-03-04 to 2021-12-13 to fit the model (dashed line). NPI: Non-pharmaceutical interventions

*Impact of higher vaccination rate:* In Figure 9, we show the results of another modeled scenario to assess the impact of the higher vaccination rate in the federal state Saarland compared to the average German vaccination rate. In the higher vaccination scenario, infections in the delta wave were significantly lower, while infections in the later omicron BA4+5 wave were significantly higher. This is likely due to the immune escape of the om scenarios, one with the actual vaccination rate and one with the reduced German vaccination<br>rate. In the higher vaccination scenario, infections in the delta wave were significantly lower,<br>while infections in the later omi rate. In the higher vaccination scenario, infections in the delta wave were significantly lower, while infections in the later omicron BA4+5 wave were significantly higher. This is likely due to the immune escape of the om while infections in the later omicron  $BA4+5$  wave were significantly higher. This is likely due<br>to the immune escape of the omicron variants regarding vaccination. However, the total<br>number of deaths remained lower in the While immune escape of the omicron variants regarding vaccination. However, the total number of deaths remained lower in the scenario observed with the higher vaccination rate, consistent with the reported lower pathogenic number of deaths remained lower in the scenario observed with the higher vaccination rate, consistent with the reported lower pathogenicity of the Omicron variant. This suggests that the higher vaccination rate in Saarland number of the death with the reported lower pathogenicity of the Omicron variant. This suggests that the higher vaccination rate in Saarland may have played a relevant role in preventing severe outcomes also in the long te consistent with the reported lower pathogenicity of the Omicron variant clusters riggers that<br>the higher vaccination rate in Saarland may have played a relevant role in preventing severe<br>outcomes also in the long term. the higher vacation rate in Saarland may have played a relevant rate in preventing severe played a relevant role in preventing severe played a relevant role in preventing severe played a relevant role in preventing severe outcomes also in the long term.

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .



Figure 9: Estimation of the impact of the higher vaccination rate in the federal state Saarland compared with the German average. A) Comparison of the reported testpositives and COVID-19 deaths (grey) with the model under the observed vaccination rate (red). In blue, we show the hypothetical scenario of the lower average German vaccination rate applied in Saarland. Under this scenario, higher infection numbers of Omicron BA4+5 would be expected but still, death toll remains lower, B) Cumulative vaccination rates in Saarland compared with Germany. The occurrence of new SARS-CoV-II variants at frequencies higher than 5% is shown as dashed lines.

Discussion<br>In this paper, we implement the early proposed method of parametrization of COVID-19 epidemiologic extended SECIR-type model [2] to explain the course of the epidemic in Germany as well as in all 16 German federal lands. Germany as well as in all 16 German federal lands.<br>As in the provious case, we embed differential equations based originals modelling into

As in the previous case, we embed differential<br>an input output dynamical exctom  $\overline{(A \cup B)}$ . an input-output dynamical system (IO-NLDs), combining explicit mechanistic models of epidemic spread and phenomenological considerations of external impacts on model parameters via the input layer. As earlier, we assumed here also a non-direct link between state parameters of the embedded SECIR model and observables. This allows interposing a data model considering known biases of the available data resources.

Our current model updates the previous one by assuming age-dependent sub-models with known contact matrix and extending virus-variant dependent sub-models from two to unlimited (currently ten). We modelled vaccination, waning and boostering as well. The resulting updates enable us to get rid of two from three empirical dynamical parameters pcrit and pdeath, explaining variations in probability to develop critical symptoms or dye to age differences, different NPI for each age category and difference between virus variants. This shows, how unexplained empirical inputs can be later mechanically modelled, when additional information becomes available. This proofs universal importance of IO-NLDs, which enable to implement all current knowledge and ready update the model. which enable to implement all current all current knowledge and ready up date the model.

We model currently also hospital station occupancy. Along with ICU we model these outputs as an additional layer "hospitalization", based indirectly on symptomatic compartments, rather than assuming separate model compartm

compartments, rather than assuming separate model compartments.<br>Based on our IO-NLDS formulation and data models, we parametrized our model on the<br>basis of data of infection numbers, critical and general hospital occupatio Example and The MLDS formulation and data models, we paramethanis of data of infection numbers, critical and general hospital contains available for Germany and Saxony. Here, we chose a full-informaticall data in between s Based on our parameters of data of infection numbers, critical and general hospital occupations, and deaths lable for Germany and Saxony. Here, we chose a full-information approach considering ata in between start of the e available for Germany and Saxony. Here, we chose a full-information approach considering<br>all data in between start of the epidemic 4 March 2020 to 12 September 2024. We also applied<br>a Bayesian learning process by consideri all data in between start of the epidemic 4 March 2020 to 12 September 2024. We also applied<br>a Bayesian learning process by considering other studies to inform model parameter's<br>settings. Thus, we combine mechanistic model a Bayesian learning process by considering other studies to inform model parameter's<br>settings. Thus, we combine mechanistic model assumptions with results from other studies<br>and observational data. This approach is very po settings. Thus, we combine mechanistic model assumptions with results from other studies<br>and observational data. This approach is very popular in pharmacology [4] but despite its<br>importance it is yet rarely applied in epid

and observational data. This approach is very popular in pharmacology [4] but despite its<br>importance it is yet rarely applied in epidemiology [5].<br>Model parametrization resulted in a good and unbiased fit of data for the p importance it is yet rarely applied in epidemiology [5].<br>
Model parametrization resulted in a good and unbiased fit of data for the period<br>
considered for Germany and all its federal lands. Fixed parameter values of the SE Model parametrization resulted in a good and<br>considered for Germany and all its federal lands. Fixed<br>did not significantly deviated from known from litera<br>intensification and relaxation events were necessary to<br>the time co I idered for Germany and all its federal lands. Fixed parameter values of the SECIR model<br>not significantly deviated from known from literature values if available. A total of 37<br>nsification and relaxation events were nece did not significantly deviated from known from literature values if available. A total of 37 intensification and relaxation events were necessary to describe the epidemic dynamics over the time course of observations for e intensification and relaxation events were necessary to describe the epidemic dynamics over<br>the time course of observations for each federal subject and each age category, i.e. 85<br>different dynamical parameters of residual

the time course of observations for each federal subject and each age category, i.e. 85<br>different dynamical parameters of residual infectivity b<sub>1</sub>.<br>We estimated higher values of b1 at the very beginning of the epidemic, w different dynamical parameters of residual infectivity b<sub>1</sub>.<br>We estimated higher values of b1 at the very beginning of the epidemic, which could be due<br>to natural contacting behaviour but could also be caused by issues reg We estimated higher values of b1 at the very beginning of the settimated higher values of b1 at the very beginning of the natural contacting behaviour but could also be cause lack of testing capacities, i.e. we cannot excl to natural contacting behaviour but could also be caused by issues regarding reporting or<br>lack of testing capacities, i.e. we cannot exclude that this is an unresolved data artifact.<br>Seasonal changes can be discernable onl lack of testing capacities, i.e. we cannot exclude that this is an unresolved data artifact.<br>Seasonal changes can be discernable only in 2020. In 2021 the seasonality cannot be clearly

thack of testing capacities, i.e. we cannot exclude that this is an unresolved data artifact.<br>Seasonal changes can be discernable only in 2020. In 2021 the seasonality cannot be clearly<br>traced. In the year 2021 the variabi shirt in the search of the traced. In the year 2021 the variability of b1 between federal states was large, exceeding<br>variability among age groups for the overall data of Germany. This is plausible because NPI<br>implementation was very heterogeneous b variability among age groups for the overall data of Germany. This is plausible because NPI<br>implementation was very heterogeneous between states. Only later in the pandemic (end of<br>2021), there were attempts to implement n implementation was very heterogeneous between states. Only later in the pandemic (end of

implementation was very distributed in the panel of NPI rules and<br>2021), there were attempts to implement nation-wide harmonization of NPI rules and<br>In 2022 b1 was mostly less than 0.2 in all age categories and stable with measures (see Error! Reference source not found.).<br>In 2022 b1 was mostly less than 0.2 in all age categories and stable with very little variability<br>between federal states, showing effectivity of these nation-wide harmoniz In 2022 between federal states, showing effectivity of these nation-wide harmonization of NPI rules.<br>Please note that the model's predictions are based solely on data and assumptions. Therefore<br>the results should be interp

Please note that the model's predictions are based solely on data and assumptions. Therefore,<br>the results should be interpreted with caution.<br>In this work we estimated 8917 parameters using more than 560000 data points: 16 In this work we estimated 8917 parameter and the view of the view of the spherical subjects for five as hospital and ICU stations occupations as well waning. points for 17 federal subjects for five age categories for new registered cases, death, bital and ICU stations occupations as well as daily age-specific data on vaccination and ing.<br>Estimated infectivity roughly correlated deally approach and ICU stations occupations as well as daily age-specific data on vaccination and<br>waning.<br>Estimated infectivity roughly correlated with the Governmental Stringency Index [29].<br>We regularly contributed fore

waning.<br>
Estimated infectivity roughly correlated with the Governmental Stringency Index [29].<br>
We regularly contributed forecasts of our model to the German forecast Hub [27].<br>
We also demonstrated utility of our model by

hospital and ICU stations of epidemic and ICU stations of epidemic derived in Saxony, a federal state of German simulations of scenarios of epidemic development in Saxony, a federal state of Germany. We could show that Estimated infections of our model to the German forecast Hub [27].<br>We also demonstrated utility of our model by several mid-term simulations of scenarios<br>pidemic development in Saxony, a federal state of Germany. We could We also demonstrated utility of our model by several mid-term simulations of epidemic development in Saxony, a federal state of Germany. We could predictions of reported infections were in the range of later observations f pidemic development in Saxony, a federal state of Germany. We could show that<br>ictions of reported infections were in the range of later observations for scenarios<br>idered likely.<br>As future extensions and improvements of our

predictions of reported infections were in the range of later observations for scenarios considered likely.<br>As future extensions and improvements of our model, we will consider stochastic effects on a daily scale, for exam predictions of infections and improvements of our model, we will consider stochastic effects<br>on a daily scale, for example to model random influxes of cases or to model random<br>extinctions of infection chains. These effects As future external<br>As future external<br>extinctions of inferincidence number<br>IO-NLDS frameword IO-NLDS framework is well suited to implement such extensions [3]. Furthermore, another application of our model is to provide infection scenarios for hospital data exposure models on a daily start, for the model is to model in Germany in the summers 2020 and 2021. Our IO-NLDS framework is well suited to implement such extensions [3]. Furthermore, another application of our model is to provide infect extinction considerate the interest of interests are relevant in the summers 2020 and 2021. Our IO-NLDS framework is well suited to implement such extensions [3]. Furthermore, another application of our model is to provide IO-NLDS framework is well suited to implement such extensions [3]. Furthermore, another application of our model is to provide infection scenarios for hospital data exposure models as previously successfully applied for ge In application of our model is to provide infection scenarios for hospital data exposure models<br>as previously successfully applied for german ICU admission forecasts or similar hospital<br>resource planning tools currently be as previously successfully applied for german ICU admission forecasts or similar hospital resource planning tools currently being developed. This leveragaes the advantage of our resource planning tools currently being deve resource planning tools currently being developed. This leveragaes the advantage of our resource planning tools currently being developed. This leveragaes the advantage of our<br>control planning to our currently being developed. This level is developed.

modell, that compartments reflecting severe course are modeled solely as output-

separation of mechanistic model compartments from random or time-dependent non-In summary, the primary focus of the paper is an adequate epidemiological models on the basis of complex, possibly biased data, as with structurally unknown dynamical external influences. This approaseparation of mechanist In summary, the printing of the paper in the paper in the paper parameteristic emiological models on the basis of complex, possibly biased data, as well as its coupling structurally unknown dynamical external influences. T epidemiological model in the basis of protecting presents. This approach allows for a clear separation of mechanistic model compartments from random or time-dependent non-<br>mechanistic influences and biases in the data. We extracturally unknown by different and the data with the operation of mechanistic influences and biases in the data. We believe that this approach is useful not only for the parametrization of the SECIR model presented her only for the parametrization of the SECIR model presented here but also for other epidemiologic models including other disease contexts and data structures.

Author Contributions: Conceptualization (ideas; formulation or evolution of overarching epidemiologic models including other disease contexts and data structures.<br> **Author Contributions:** Conceptualization (ideas; formulation or evolution of overarching<br>
research goals and aims): H.K. and M.S.; data curation epidemic models in the contributions: Conceptualization (ideas; formulation or evolution research goals and aims): H.K. and M.S.; data curation (management action). h<br>c Author Contributions: Conceptualization (ideas, formulation or evolution or overarching<br>research goals and aims): H.K. and M.S.; data curation (management activities to annotate<br>(produce metadata), scrub data and maintain (produce metadata), scrub data and maintain research data (including software code, where it is necessary for interpreting the data itself) for initial use and later reuse): H.K.; formal analysis (application of statistica it is necessary for interpreting the data itself) for initial use and later reuse): H.K.; formal analysis (application of statistical, mathematical, computational, or other formal techniques to analyze or synthesize study collection): Y.K., H.K., and M.S.; methodology (development or design of methodology; analyze (expression of synthesize study data): Y.K.; funding acquisition (acquisition of the financial support for the project leading to this publication): A.S. and M.S.; investigation (conducting a research and investiga to analyze the project leading to this publication): A.S. and M.S.; investigation (conducting a research and investigation process, specifically performing the experiments, or data/evidence collection): Y.K., H.K., and M.S research and investigation process, specifically performing the experiments, or data/evidence<br>collection): Y.K., H.K., and M.S.; methodology (development or design of methodology;<br>creation of models): Y.K., M.S., and H.K.; research and investigation process, specifically process collection): Y.K., H.K., and M.S.; methodology (development or design of methodology; creation of models): Y.K., M.S., and H.K.; project administration (management a creation of models): Y.K., M.S., and H.K.; project administration (management and coordination responsibility for the research activity planning and execution): A.S. and M.S.; resources (provision of study materials, reage coordination responsibility for the research activity planning and execution): A.S. and M.S.;<br>resources (provision of study materials, reagents, materials, patients, laboratory samples,<br>animals, instrumentation, computing colume the responsibility for the research activity planning and interestingly resources (provision of study materials, reagents, materials, patients, laboratory samples, animals, instrumentation, computing resources, or o resources (provision of study materials, reagency materials, patterials, instrumentation, computing resources, or other analysis tools): H.K.; software (programming, software development; designing computer programs; imple and programming, software development; designing computer programs; implementation of the computer code and supporting algorithms; testing of existing code components): Y.K. and H.K.; supervision (oversight and leadership (programming) returns are truppentity arrigining religions programs, in promption computer code and supporting algorithms; testing of existing code components): Y.K. and H.K.; supervision (oversight and leadership responsi Example 2012 The and supporting and execution, including mentorship external to the core team): M.S.; validation (verification, whether as a part of the activity or separate, of the overall replication/reproducibility of r and execution, including mentorship external to the core team): M.S.; validation (verification, whether as a part of the activity or separate, of the overall replication/reproducibility of results/experiments and other res and executive, including mention, whether as a part of the activity or separate, of the overall replication/reproducibility of results/experiments and other research outputs): H.K. and M.S.; visualization (preparation, cre whether as a part of the research outputs): H.K. and M.S.; visualization (preparation, creation and/or presentation of the published work, specifically visualization/data presentation): H.K., writing—original draft prepara creation and/or presentation of the published work, specifically visualization/data<br>presentation): H.K., writing—original draft preparation (creation and/or presentation of the<br>published work, specifically writing the init presentation): H.K., writing—original draft preparation (creation and/or presentation of the published work, specifically writing the initial draft (including substantive translation)): Y.K., H.K., and M.S.; writing—review published work, specifically writing the initial draft (including substantive translation)): Y.K., H.K., and M.S.; writing—review and editing (preparation, creation and/or presentation of the published work by those from t of the published work by those from the original research group, specifically critical review, Y. H. H., H.K., A.S. and the published work by those from the original research group, specifically critical review, commentary or revision—including pre- or post-publication stages): Y.K., H.K., A.S. and M.S. All authors

commentary or revision—including pre- or post-publication stages): Y.K., H.K., A.S. and<br>M.S. All authors have read and agreed to the published version of the manuscript.<br>**Funding:** This project was funded by the German Fed M.S. All authors have read and agreed to the published version of the manuscript.<br> **Funding:** This project was funded by the German Federal Ministry of Education and<br>
Research (BMBF 031L0296A ("PROGNOSIS") with respect to Funding: This project was funded by the German Federal Ministry of Educk<br>Research (BMBF 031L0296A ("PROGNOSIS") with respect to updating the epic<br>model and BMBF 031L0299E ("OptimAgent") with respect to estimating fec<br>heter Funding: This project was funded by the German Federal Ministry of Education and<br>Research (BMBF 031L0296A ("PROGNOSIS") with respect to updating federal state<br>model and BMBF 031L0299E ("OptimAgent") with respect to estimat

model and BMBF 031L0299E ("OptimAgent") with respect to estimating federal state<br>heterogeneity).<br>**Institutional Review Board Statement:** Ethical review and approval were waived for this<br>study as only published data from of model and BMBF 1999. The BMBF of the Channing Federal Statement: Anti-<br>Institutional Review Board Statement: Ethical review and approval were waived for this<br>study as only published data from official sources was used (see Institutional R<br>Study as only <sub>1</sub><br>description of d<br>Informed Cons Informed Consent Statement: Patient consent was waived (see manuscript for detailed description of data sources).<br> **Informed Consent Statement:** Patient consent was waived for this study as only published data from officia

state) as tealy published<br>description of data sources).<br>Informed Consent Statement: Patient consent was waived for this study as only published<br>data from official sources was used (see manuscript for detailed description o

description of data sources).<br>Informed Consent Statemer<br>data from official sources wa<br>Data Availability Stater<br>https://github.com/GenStatL data from official sources was used (see manuscript for detailed description of data sources).<br> **Data** Availability Statement: Code and data is available via GitHub as https://github.com/GenStatLeipzig/Modelling-dynamics-o Data Availability Statement: Code and data is available via GitHub at<br>https://github.com/GenStatLeipzig/Modelling-dynamics-of-SARS-CoV-2-pandemics-of-<br>Germany and in the Health Atlas https://www.health-atlas.de/models/40 Data Avanability Statement: Code and data is available via GitTitub at<br>https://github.com/GenStatLeipzig/Modelling-dynamics-of-SARS-CoV-2-pandemics-of-<br>Germany and in the Health Atlas https://www.health-atlas.de/models/40  $\frac{d}{dt}$ 

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

#### Acknowledgement

**Conflicts of Interest:** The authors declare no conflict of interest.<br> **Acknowledgement**<br>
We thank Ministerial Director Daniel Stich from the Ministry of Science and Health<br>
Rhineland–Palatinate (MWG) for funding SentiSurv Rhineland–Palatinate (MWG) for funding SentiSurv, Prof. Dr. Philipp Wild, Rieke<br>Baumkötter, Simge Yilmaz, and the team from the University Medical Center Mainz for<br>making the SentiSurv data available for our study, and the Baumkötter, Simge Yilmaz, and the team from the University Medical Center Mainz for making the SentiSurv data available for our study, and the thousands of participants who contributed to public health through their commit Baumation, Similar Pillar, and the team from the Station, and the thousands of participants who contributed to public health through their commitment to the SentiSurv study<br>References making the Sentisure for the Sentisurv data available for our study, and the thousands of participants whose contributed to public health through their commitment to the SentiSurv study,<br>References<br>1. Kong L, Duan M, Shi J

## References

- **Contributed to public health through through through Neferences**<br>1. Kong L, Duan M, Shi J, Hong J, Chang Z, Zhang Z. Compartmental structures used<br>COVID-19: a scoping review. Infect Dis Poverty. 2022; 11:72. Epub 2022/06/
- 
- 1. Covid-19: a scoping review. Infect Dis Poverty. 2022; 11:72. Epub 2022/06/21.<br>
1. Covid-19: a scoping review. Infect Dis Poverty. 2022; 11:72. Epub 2022/06/21.<br>
2. Kheifetz Y, Kirsten H, Scholz M. On the Parametrization doi: 10.1186/s40249-022-01001-y PMID: 35729655.<br>Kheifetz Y, Kirsten H, Scholz M. On the Parametrization of Epidemiologic Model<br>Modelling COVID-19 Epidemic. Viruses. 2022; 14. doi: 10.3390/v14071468 PMII<br>Georgatzis K, Willi Kheifetz Y, Kirsten H, Scholz M. On the Parametrization<br>Modelling COVID-19 Epidemic. Viruses. 2022; 14. doi<br>Georgatzis K, Williams CKI, Hawthorne C. Input-Outp<br>to Physiological Condition Monitoring. Proceedings c<br>Conferenc Modelling COVID-19 Epidemic. Viruses. 2022; 14. doi: 10.3390/v14071468 PMID: 35891447.<br>
3. Georgatzis K, Williams CKI, Hawthorne C. Input-Output Non-Linear Dynamical Systems applied<br>
to Physiological Condition Monitoring. Georgatzis K, Williams CKI, Hawthorne C. Input-Output Non-Linear Dynamical Systems applie<br>to Physiological Condition Monitoring. Proceedings of the 1st Machine Learning for Healthca<br>Conference 2016: PMLR; 19 August 2016 th 1. The Physiological Communication Monitoring. Proceedings of the 1st Machine Learning for Healthcare<br>
1. Gonference 2016: PMLR; 19 August 2016 through 20 August 2016 [updated 2016 Aug 19<br>
1. Friberg LE, Henningsson A, Maa
- 
- Conference 2016: PMLR; 19 August 2016 through 20 August 2016 [updated 2016 Aug 19<br>through 2016 Aug 20].<br>Triberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced<br>myelosuppression with paramete through 2016 Aug 20].<br>
Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-indu<br>
myelosuppression with parameter consistency across drugs. J Clin Oncol. 2002; 20:4713-<br>
doi: 10.1200/JCO.2002.02. Friberg LE, Henningsson<br>
myelosuppression with<br>
doi: 10.1200/JCO.2002<br>
Dehning J, Zierenberg J<br>
points in the spread of<br>
Epub 2020/05/15. doi:<br>
Schuppert A, Theisen S<br>
Belastungsmodell für Ir<br>
Epub 2021/02/03. doi:<br>
Mosson myleosuppression with parameter consistency across drugs. J Clin Oncol. 2002; 20:4713–21.<br>
doi: 10.1200/JCO.2002.02.140 PMID: 12488418.<br>
Dehning J, Zierenberg J, Spitzner FP, Wibral M, Neto JP, Wilczek M, et al. Inferring mdistrian and Deltischland. Robert Koch-Institut; 2020.<br>The Helping J, Zierenberg J, Spitzner FP, Wibral M, Neto JP, Wilczek M, et al. Inferring change<br>points in the spread of COVID-19 reveals the effectiveness of interven Dehning J, Zierenberg J, Spitzner FP, Wibral M, N<br>points in the spread of COVID-19 reveals the effe<br>Epub 2020/05/15. doi: 10.1126/science.abb9789<br>Schuppert A, Theisen S, Fränkel P, Weber-Carster<br>Belastungsmodell für Intens
- 5. Dependent Inc. and Schware H, Spitzner M, Saragian M, et al. Evidence for The United P, Coombe M, Garlock ES, Lau WYV, Saraswat M, et al. Evidence for The United LC, Stockdale JE, Coombe M, Garlock ES, Lau WYV, Saraswat Compete 1 (Solic 10.1126/science.abb9789 PMID: 32414780.<br>
Schuppert A, Theisen S, Fränkel P, Weber-Carstens S, Karagiannidis C. Bundesweites<br>
Belastungsmodell für Intensivstationen durch COVID-19. Med Klin Intensivmed Notf Schuppert A, Theisen S, Fränkel P, Weber-Carstens S, Karagiannidis<br>Belastungsmodell für Intensivstationen durch COVID-19. Med Klin II<br>Epub 2021/02/03. doi: 10.1007/s00063-021-00791-7 PMID: 335339<br>Mossong J, Hens N, Jit M,
- Epub 2021/02/03. doi: 10.1007/s00063-021-00791-7 PMID: 33533980.<br>Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social contacts and mixing<br>patterns relevant to the spread of infectious diseases. PLoS
- 
- Exampler and Schupper A, Garlock ES, Lau WY, Saraswat M, et al. Investigation of COVID-19. Med Klin Intensivmed Notfra Figure 2021/02/03. doi: 10.1007/s00063-021-00791-7 PMID: 33533980.<br>
7. Mossong J, Hens N, Jit M, Beutel
- 
- Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Soc<br>patterns relevant to the spread of infectious diseases. PLoS Med. 2008;<br>doi: 10.1371/journal.pmed.0050074 PMID: 18366252.<br>Der Heiden M an, Buchholz 2. Moss I, Hens N, Hens M, Buchholz U, Corman VM, Hoch M, Katz K, Marosevic DV, et al. Investigation of a COVID-19 outbreak in Germany resulting from a single lszenarien der SARS-CoV-2-Ausbreitung<br>
2. Mishiura H, Linton NM doi: 10.1371/journal.pmed.0050074 PMID: 18366252.<br>Der Heiden M an, Buchholz U. Modellierung von Beispielszenarien der SARS-Co<br>und Schwere in Deutschland. Robert Koch-Institut; 2020.<br>Nishiura H, Linton NM, Akhmetzhanov AR. ner Heiden M an, Buchholz U. Modellierung von Beispi<br>und Schwere in Deutschland. Robert Koch-Institut; 202<br>Nishiura H, Linton NM, Akhmetzhanov AR. Serial interv<br>infections. Int J Infect Dis. 2020; 93:284–6. Epub 2020/<br>PMID 9. Nishiura H, Linton NM, Akhmetzhanov AR. Serial interval of novel coronavirus (COVID-19)<br>
infections. Int J Infect Dis. 2020; 93:284–6. Epub 2020/03/04. doi: 10.1016/j.ijid.2020.02.060<br>
PMID: 32145466.<br>
10. Tindale LC, S Nishiura H, Linton NM, Akhmetzhanov AR. Serial interval<br>infections. Int J Infect Dis. 2020; 93:284–6. Epub 2020/03,<br>PMID: 32145466.<br>Tindale LC, Stockdale JE, Coombe M, Garlock ES, Lau WYV<br>transmission of COVID-19 prior to 9. Infections. Int J Infect Dis. 2020; 93:284–6. Epub 2020/03/04. doi: 10.1016/j.ijid.2020.02.0<br>
9. PMID: 32145466.<br>
10. Tindale LC, Stockdale JE, Coombe M, Garlock ES, Lau WYV, Saraswat M, et al. Evidence for<br>
10. Tindale PMID: 32145466.<br>
Tindale LC, Stockdale JE, Coombe M, Garlock ES, Lau WYV, Saraswat M, et al. Evidence for<br>
transmission of COVID-19 prior to symptom onset. Elife. 2020; 9. Epub 2020/06/22.<br>
doi: 10.7554/eLife.57149 PMID: 3 Tindale LC, Stockd<br>transmission of CC<br>doi: 10.7554/eLife<br>Böhmer MM, Bucl<br>COVID-19 outbrea<br>series. The Lancet<br>Ganyani T, Kreme<br>interval for corona<br>Surveill. 2020; 25. 11. Transmission of COVID-19 prior to symptom onset. Elife. 2020; 9. Epub 2020/06/22.<br>
11. Böhmer MM, Buchholz U, Corman VM, Hoch M, Katz K, Marosevic DV, et al. Investigation cOVID-19 outbreak in Germany resulting from a doi: 10.7554/eLife.57149 PMID: 32568070.<br>Böhmer MM, Buchholz U, Corman VM, Hoch M, Katz K, Marosevic DV, et al. Investig<br>COVID-19 outbreak in Germany resulting from a single travel-associated primary cas<br>series. The Lancet Böhmer MM, Buchholz U, Corman VM, Hoc<br>COVID-19 outbreak in Germany resulting fro<br>series. The Lancet Infectious Diseases. 2020<br>Ganyani T, Kremer C, Chen D, Torneri A, Fae<br>interval for coronavirus disease (COVID-19)<br>Surveill
- 11. CoVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case<br>
series. The Lancet Infectious Diseases. 2020; 20:920-8. doi: 10.1016/S1473-3099(20)30314-5.<br>
12. Ganyani T, Kremer C, Chen D, series. The Lancet Infectious Diseases. 2020; 20:920–8. doi: 10.1016/S1473-3099(20)30314-5.<br>Ganyani T, Kremer C, Chen D, Torneri A, Faes C, Wallinga J, et al. Estimating the generation<br>interval for coronavirus disease (COV Ganyani T, Kremer C, Chen D, Torneri A, Faes C, Wallinga J, et al. Estimating the generation<br>interval for coronavirus disease (COVID-19) based on symptom onset data, March 2020. Euro<br>Surveill. 2020; 25. doi: 10.2807/1560-7 12. Ganyani T, Marina J, Then D, Theorist, Yangon, Yangon, Yangon, Yangon, Yangon, Bandaning the generation<br>interval for coronavirus disease (COVID-19) based on symptom onset data, March 2020. Eu<br>Surveill. 2020; 25. doi: 1 interval for coronavirus disease (COVID-19) based on yin point once data, March 2020 and<br>Surveill. 2020; 25. doi: 10.2807/1560-7917.ES.2020.25.17.2000257 PMID: 32372755. Surveill. 2020; 25. doi: 10.2807/1560-7917.ES.2020.25.17.2000257 PMID: 32372755.
- 
- 
- 
- 
- 11. Show F, Buda Content P, Michael at a are trospective cohort study. The Lancet. 2020;<br>1395:1054-62. doi: 10.1016/S0140-6736(20)30566-3.<br>14. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High Contagiousn 395:1054–62. doi: 10.1016/S0140-6736(20)30566-3.<br>Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High Contagiousness and Ra<br>Spread of Severe Acute Respiratory Syndrome Coronavirus 2. Emerg Infect Dis. 2020; Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartn<br>Spread of Severe Acute Respiratory Syndrome Coron:<br>7. Epub 2020/06/21. doi: 10.3201/eid2607.200282 PI<br>COVID-19 National Emergency Response Center. Coron:<br>in the Republic 14. Sanche S, Lin Yamay 19. Sanche S, Lin Yamay 19. Spead of Severe Acute Respiratory Syndrome Coronavirus 2. Emerg Infect Dis. 2020; 26:1470–7. Epub 2020/06/21. doi: 10.3201/eid2607.200282 PMID: 32255761.<br>
15. COVID-19 Na 7. Epub 2020/06/21. doi: 10.3201/eid2607.200282 PMID: 32255761.<br>COVID-19 National Emergency Response Center. Coronavirus Disease-19: The First 7,755 Cases<br>in the Republic of Korea. Osong Public Health Res Perspect. 2020; 1 COVID-19 National Emergency Response Center. Coronavirus Disease<br>in the Republic of Korea. Osong Public Health Res Perspect. 2020; 11:<br>doi: 10.24171/j.phrp.2020.11.2.05 PMID: 32257774.<br>Tolksdorf K, Buda S, Schuler E, Wiele 16. The Republic of Korea. Osong Public Health Res Perspect. 2020; 11:85–90.<br>
16. Tolksdorf K, Buda S, Schuler E, Wieler LH, Haas W. Eine höhere Letalität und lange<br>
16. Tolksdorf K, Buda S, Schuler E, Wieler LH, Haas W. E doi: 10.24171/j.phrp.2020.11.2.05 PMID: 32257774.<br>Tolksdorf K, Buda S, Schuler E, Wieler LH, Haas W. Eine höhere Letalität und leatmungsdauer unterscheiden COVID-19 von schwer verlaufenden Atemwe<br>Grippewellen. 2020. Epub 2 Tolksdorf K, Buda S, Schuler E, Wieler LH, Haas W. Eir<br>Beatmungsdauer unterscheiden COVID-19 von schwe<br>Grippewellen. 2020. Epub 2020/08/28. doi: 10.25646<br>Karagiannidis C, Mostert C, Hentschker C, Voshaar T,<br>characteristics Beatmungsdauer unterscheiden COVID-19 von schwer verlaufenden Atemwegsinf-<br>
Grippewellen. 2020. Epub 2020/08/28. doi: 10.25646/7111.<br>
17. Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al Grippewellen. 2020. Epub 2020/08/28. doi: 10.25646/7111.<br>Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al. Case<br>characteristics, resource use, and outcomes of 10 021 patients with COVIDregiannidis C, Mostert C, Hentschker C, Voshaar T, Malzah<br>characteristics, resource use, and outcomes of 10 021 patien<br>German hospitals: an observational study. The Lancet Respir<br>doi: 10.1016/S2213-2600(20)30316-7.<br>Linton
- 17. Karagiannidis C, Hentscher C, Instanting C, GS13.<br>
17. Karacteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted 1<br>
German hospitals: an observational study. The Lancet Respiratory Medicine. German hospitals: an observational study. The Lancet Respiratory Medicine. 2020; 8:853–62.<br>doi: 10.1016/S2213-2600(20)30316-7.<br>Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung S-M, et al. Incubation<br>Period doi: 10.1016/S2213-2600(20)30316-7.<br>Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung S-M, et al. Incubation<br>Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with<br>Right T Linton NM, Kobayashi T, Yang Y, Hayasl<br>Period and Other Epidemiological Char<br>Right Truncation: A Statistical Analysis<br>2020/02/17. doi: 10.3390/jcm9020538<br>Verity R, Okell LC, Dorigatti I, Winskill P<br>coronavirus disease 2019 18. Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with<br>
18. Right Truncation: A Statistical Analysis of Publicly Available Case Data. J Clin Med. 2020; 9.<br>
19. Verity R, Okell LC, Do
- 2020/02/17. doi: 10.3390/jcm9020538. PMID: 32079150.<br>Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of<br>coronavirus disease 2019: a model-based analysis. The Lancet Infect
- Report Truncation: A Statistical Analysis of Publicly Available Case Data. J Clin Med. 2020; 9. E<br>2020/02/17. doi: 10.3390/jcm9020538. PMID: 32079150.<br>2020/02/17. doi: 10.3390/jcm9020538. PMID: 32079150.<br>Verity R, Okell LC
- 
- 
- 
- Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai<br>coronavirus disease 2019: a model-based analysis. The Lar<br>20:669–77. doi: 10.1016/S1473-3099(20)30243-7.<br>Bock W, Jayathunga Y, Götz T, Rockenfeller R. Are the 19. Verify and the several conductions of the landship of the several coronavirus disease 2019: a model-based analysis. The Lancet Infectious Diseases. 2020;<br>
20. 669–77. doi: 10.1016/S1473-3099(20)30243-7.<br>
20. Bock W, Ja 20:669–77. doi: 10.1016/S1473-3099(20)30243-7.<br>
Bock W, Jayathunga Y, Götz T, Rockenfeller R. Are the upper bounds for new SARS-CoV-2<br>
infections in Germany useful. Computational and Mathematical Biophysics. 2021; 9:242–<br> Bock W, Jayathunga Y, Götz T, Rockenfeller R. Are t<br>infections in Germany useful. Computational and N<br>doi: 10.1515/cmb-2020-0126.<br>https://www.divi.de/divi-intensivregister-tagesrep<br>DIVI 2020 [updated 30 Jun 2022].<br>Robert-K infections in Germany useful. Computational and Mathematical Biophysics. 2021; 9:242–1<br>
doi: 10.1515/cmb-2020-0126.<br>
21. https://www.divi.de/divi-intensivregister-tagesreport-. Tagesreport-Archiv. Tagesreport-<br>
DIVI 2020 [ infections in Germany and Mathematical Biophysics. The state of th https://www.divi.de/divi-inten<br>DIVI 2020 [updated 30 Jun 202<br>Robert-Koch Institut, editor. C(<br>https://github.com/robert-koc<br>Robert Koch-Institut. SARS-Co\<br>Bericht zu Virusvarianten von S<br>(VOC) B.1.1.7. Robert Koch Ins<br>http 22. Robert-Koch Institute, education and Statistical Problems. J ACM.<br>22. Hobert-Koch Institut, editor. COVID-19 Hospitalisierungen in Deutschland. 2024. Available from:<br>23. Robert Koch-Institut. SARS-CoV-2 Sequenzdaten au Robert-Koch Institut, editor. COVI<br>
https://github.com/robert-koch-ir<br>
Robert Koch-Institut. SARS-CoV-2<br>
Bericht zu Virusvarianten von SAR<br>
(VOC) B.1.1.7. Robert Koch Institut<br>
https://www.rki.de/DE/Content/II<br>
03-03.pdf?\_ 22. Robert Koch Institut, SARS-Cov-2 Sequenzdaten aus Deutschland. Zenodo; 2023.<br>
23. Robert Koch-Institut. SARS-Cov-2 Sequenzdaten aus Deutschland. Zenodo; 2023.<br>
24. Bericht zu Virusvarianten von SARS-Cov-2 in Deutschlan Robert Koch-Institut. SARS-CoV-2 Sequenzdaten aus Deutschland. Zenodo; 2023.<br>Bericht zu Virusvarianten von SARS-CoV-2 in Deutschland, insbesondere zur Variant of C<br>(VOC) B.1.1.7. Robert Koch Institute [updated 3 Mar 2021; 24. Bericht zu Virusvarianten von SARS-CoV-2 in Deutschland, insbesondere zur Varia<br>
(VOC) B.1.1.7. Robert Koch Institute [updated 3 Mar 2021; cited 3 Mar 2021]. Ava<br>
https://www.rki.de/DE/Content/InfAZ/N/Neuartiges\_Corona (VOC) B.1.1.7. Robert Koch Institute [updated 3 Mar 2021; cited 3 Mar 2021]. Available from:<br>
https://www.rki.de/DE/Content/InfAZ/N/Neuartiges\_Coronavirus/DESH/Bericht\_VOC\_2021-<br>
03-03.pdf?\_blob=publicationFile.<br>
25. Kheif
- (Vocal Of Leader) Music (September Content/Infaz/N/Neuartiges\_Coronavirus/DESH/Bericht\_VOC\_2021-<br>03-03.pdf?\_\_blob=publicationFile.<br>Kheifetz Y, Scholz M. Modeling individual time courses of thrombopoiesis during multi-cycli 03-03.pdf?\_blob=publicationFile.<br>
Rheifetz Y, Scholz M. Modeling individual time courses of thrombopoiesis during multi-cyclic<br>
chemotherapy. PLoS Comput Biol. 2019; 15:e1006775. Epub 2019/03/06.<br>
doi: 10.1371/journal.pcbi Enterty Collect Premium in External<br>
Kheifetz Y, Scholz M. Modeling indi<br>
chemotherapy. PLoS Comput Biol. 1<br>
doi: 10.1371/journal.pcbi.1006775<br>
Advances in neural information pro<br>
Hooke R, Jeeves TA. `` Direct Searcl<br>
1961 26. Kheifetz Y, PLOS Comput Biol. 2019; 15:e1006775. Epub 2019/03/06.<br>
26. Advances in neural information processing systems. ; 1990.<br>
26. Advances in neural information processing systems. ; 1990.<br>
27. Hooke R, Jeeves TA.
- 
- 
- 
- doi: 10.1371/journal.pcbi.1006775 PMID: 30840616.<br>Advances in neural information processing systems. ; 1990.<br>Hooke R, Jeeves TA. `` Direct Search'' Solution of Numerical and Statistical<br>1961; 8:212–29. doi: 10.1145/321062. Advances in neural information processing systems.;<br>Advances in neural information processing systems.;<br>Hooke R, Jeeves TA. `` Direct Search'' Solution of Nun<br>1961; 8:212–29. doi: 10.1145/321062.321069.<br>Kreutz C, Raue A, K 27. Hooke R, Jeeves TA. `` Direct Search'' Solution of Numerical<br>1961; 8:212–29. doi: 10.1145/321062.321069.<br>28. Kreutz C, Raue A, Kaschek D, Timmer J. Profile likelihood in s<br>280:2564–71. Epub 2013/05/09. doi: 10.1111/feb 27. Hooke R, Jeeves TA. `` Direct Search'' Solution of Numerical and Statistical Problems. J ACM.<br>1961; 8:212–29. doi: 10.1145/321062.321069.<br>28. Kreutz C, Raue A, Kaschek D, Timmer J. Profile likelihood in systems biology 1961; 8:212–20. doi: 10.1112–20. doi: 10.1111/f<br>Kreutz C, Raue A, Kaschek D, Timmer J. Profile |<br>280:2564–71. Epub 2013/05/09. doi: 10.1111/f<br>https://www.bsg.ox.ac.uk/research/research<br>r. COVID-19 Government Response Track 280:2564–71. Epub 2013/05/09. doi: 10.1111/febs.12276 PMID: 23581573.<br>28. https://www.bsg.ox.ac.uk/research/research-projects/covid-19-government-response-<br>tracker. COVID-19 Government Response Tracker. University of Oxfor 280:25764–2014) https://www.bsg.ox.ac.uk/research/research-projects/covid-19-government.<br>COVID-19 Government Response Tracker. University of Oxford 2020 [upd:<br>Tracker. University of Oxford 2020 [upd: 20. https://www.bsg.ox.ac.uk/research/research-projects/covid-19-government-response-<br>tracker. COVID-19-Government-Response-Tracker. University of Oxford-2020 [updated-3 Mar 20<br>Altracker. COVID-19-Government-Response-Track tracker. COVID-19 Government Response Tracker. University of Oxford 2020 [updated 3 Mar 2022].

medRxiv preprint doi: [https://doi.org/10.1101/2024.11.11.24317088;](https://doi.org/10.1101/2024.11.11.24317088) this version posted November 11, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

medRxiv preprint doi: [https://doi.org/10.1101/2024.11.11.24317088;](https://doi.org/10.1101/2024.11.11.24317088) this version posted November 11, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .



Appendix N. Estimation of age-group specific temporal dynamics of immune states of infected subjects **Error! Bookmark** not defined.